Skip to main content
EyePoint Pharmaceuticals, Inc. logo

EyePoint Pharmaceuticals, Inc. — Investor Relations & Filings

Ticker · EYPT ISIN · US74440J1016 LEI · 549300QE1RU34T50MR69 US Manufacturing
Open in API
Filings indexed 1,019 across all filing types
Latest filing 2014-02-14 Major Shareholding Noti…
Country US United States of America
Listing US EYPT

About EyePoint Pharmaceuticals, Inc.

https://eyepointpharma.com/

EyePoint Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for serious retinal diseases. The company leverages its proprietary Durasert E™ technology, a bio-erodible platform for sustained intraocular drug delivery, to create durable therapies. Its lead investigational product, DURAVYU™ (EYP-1901), combines the tyrosine kinase inhibitor vorolanib with the Durasert E™ system for the potential treatment of VEGF-mediated retinal diseases. The company's goal is to improve patient outcomes and reduce treatment burden by providing long-lasting treatments for chronic eye conditions.

Recent filings

Filing Released Lang Actions
Major Shareholding Notification 2014
Major Shareholding Notification
2014-02-14 English
FORM 10-Q
Interim / Quarterly Report Q2 2014
2014-02-12 English
8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated February 7, 2014, reporting the issuance of a press release announcing the company's second quarter fiscal year 2014 results. The text explicitly states that the press release is furnished as an exhibit and that the information is not filed for purposes of Section 18 and is not incorporated by reference into other filings. The document is short (2649 characters) and primarily serves to announce the earnings release via a press release rather than containing the financial results itself. According to the 'Menu vs Meal' rule, this is an announcement of a report (the press release) rather than the report itself. Therefore, the appropriate classification is Earnings Release (ER), as the document announces quarterly financial results, but since the actual financial data is in the press release exhibit, this 8-K serves as the initial announcement of quarterly results.
2014-02-07 English
FORM 8-K
Board/Management Information Classification · 100% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The specific item reported is the resignation of a director, Paul A. Hopper, effective January 17, 2014. This corresponds to a change in the company's board of directors. The document is short (2087 characters) and focuses solely on management change, with no financial data or other report content. Therefore, it fits the category of Board/Management Information (MANG).
2014-01-21 English
FORM 8-K
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated December 18, 2013, reporting the submission of matters to a vote of security holders at the company's annual meeting. It details the voting results on various proposals including election of directors, stock option grants, ratification of stock issuance, advisory votes on executive compensation, and appointment of auditors. The content is focused on the official results from shareholder votes at the annual meeting. The document length is 4422 characters, which is relatively short but contains detailed voting results, not just an announcement of a report. The key section is 'Item 5.07 Submission of Matters to a Vote of Security Holders,' which aligns with the category for Declaration of Voting Results & Voting Rights Announcements (DVA). Therefore, the correct classification is DVA with high confidence.
2013-12-23 English
FORM 8-K
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated December 19, 2013, by pSivida Corp. It announces the entry into a material definitive agreement, specifically an At Market Issuance Sales Agreement for issuing and selling common stock. The content focuses on financing activities, including details about the sales agreement, commission, and indemnification. There are no financial statements or earnings data presented, nor is it a report of voting results, management changes, or legal proceedings. The primary subject is a capital raising arrangement. Therefore, this filing fits the Capital/Financing Update category (CAP). The document length is 4420 characters, which is sufficient to contain substantive information about the financing agreement rather than just an announcement of a report publication or a regulatory filing. Hence, the classification is CAP with high confidence.
2013-12-20 English

Browse filings by year

19 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.